GlassScriptPhysician profile
Archil Abashidze
NPI 1891717757
$4,165.26
in general payments reported to CMS, 2019-2025
17 companies · $989 in 2025
The $989 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $287 · 2021: $511 · 2022: $531 · 2023: $817 · 2024: $566 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $24.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.36 |
| Education | $24.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $883.30 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $781.01 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $706.97 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $624.29 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $226.83 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.28 | 2020-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $159.52 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $158.94 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $114.84 | 2019-2025 | Uzedy, Austedo Xr |
| Allergan, INC. | $85.81 | 2020 | |
| Axsome Therapeutics, INC. | $60.77 | 2022-2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $47.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.66 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.58 | 2021-2022 | |
| Janssen Biotech, INC. | $22.06 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $20.16 | 2021 | |
| Tms Neurohealth Centers INC. | $15.97 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archil Abashidze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.